Evidence map›Paper›PMID 39414270›Full record

ArticleBMJ open2024

What is the carbon footprint of academic clinical trials? A study of hotspots in 10 trials.

Jessica Griffiths, Fiona Adshead, Rustam Al-Shahi Salman, Craig Anderson, Emma Bedson, Judith Bliss, Ana Boshoff, Xiaoying Chen, Denise Cranley, Peter Doran and 20 more

Abstract read
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Jessica GriffithsClinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK jessica.griffiths@icr.ac.uk.ORCID http://orcid.org/0009-0006-2406-3796
Fiona AdsheadSustainable Healthcare Coalition, London, UK.
Rustam Al-Shahi SalmanEdinburgh Clinical Trials Unit, The University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0002-2108-9222
Craig AndersonGeorge Institute for Global Health, Camperdown, New South Wales, Australia.
Emma BedsonLiverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK.
Judith BlissClinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
Ana BoshoffImperial Clinical Trials Unit, Imperial College London, London, UK.
Xiaoying ChenGeorge Institute for Global Health, Camperdown, New South Wales, Australia.
Denise CranleyEdinburgh Clinical Trials Unit, The University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0001-5360-9950
Peter DoranUniversity College Dublin, Dublin, Ireland.
Fidelma DunneCTN Diabetes and Institute for Clinical Trials, University of Galway, Galway, Ireland.
Carrol GambleLiverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK.
Katie GilliesHealth Services Research Unit, University of Aberdeen, Aberdeen, UK.ORCID http://orcid.org/0000-0001-7890-2854
Kerenza HoodCentre for Trials Research, Cardiff University, Cardiff, UK.
Columb KavanaghTrinity College Dublin, Dublin, Ireland.
Julia MaloneCancer Trials Ireland, Dublin, Ireland.
Naomi McGregorNewcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.
Carolyn McNamaraTechnology & Innovation, KCR, London, UK.
Elis MidhaCardiff University School of Medicine, Cardiff, UK.
Keith MooreSustainable Healthcare Coalition, London, UK.
Lucy MurphyCancer Trials Ireland, Dublin, Ireland.
Christine NewmanCTN Diabetes and Institute for Clinical Trials, University of Galway, Galway, Ireland.
Seamus O'ReillyCancer Trials Ireland, Dublin, Ireland.
Alexis M PerkinsImperial Clinical Trials Unit, Imperial College London, London, UK.
Sarah PettMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Matthew Robert SydesMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.ORCID http://orcid.org/0000-0002-9323-1371
Laura WhittyLiverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK.
Frank YouHealth Services Research Unit, University of Aberdeen, Aberdeen, UK.
Lisa FoxClinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
Paula R WilliamsonUniversity of Liverpool, Liverpool, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical trials are fundamental to healthcare, however, they also contribute to anthropogenic climate change. Following previous work to develop and test a method and guidance to calculate the carbon footprint of clinical trials, we have now applied the guidance to 10 further UK and international, academically sponsored clinical trials to continue the identification of hotspots and opportunities for lower carbon trial design.

methods10 collaborating clinical trial units (CTUs) self-identified and a trial was selected from their portfolio to represent a variety of designs, health areas and interventions. Trial activity data was collated by trial teams across 10 modules spanning trial setup through to closure, then multiplied by emission factors provided in the guidance to calculate the carbon footprint. Feedback was collected from trial teams on the process, experience and ease of use of the guidance.

resultsWe footprinted 10 trials: 6 investigational medicinal product trials, 1 nutritional, 1 surgical, 1 health surveillance and one complex intervention trial. Six of these were completed and four ongoing (two in follow-up and two recruiting). The carbon footprint of the 10 trials ranged from 16 to 765 tonnes CO DISCUSSION: There are opportunities to reduce the impact of trials across all modules, particularly trial-specific meetings and travel, patient assessments and laboratory practice. A trial's carbon footprint should be considered at the design stage, but work is required to make this common place.

Indexed as

Carbon FootprintClinical Trials as TopicClimate ChangeHumansResearch DesignUnited Kingdomclimate changeclinical trialrandomized controlled trialstatistics & research methods

Identifiers

PMID39414270
PMCPMC11487931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.